SUZHOU, China, April 12, 2022 /PRNewswire/ -- MediLink Therapeutics announced that YL201, the first compound based on MediLink's proprietary antibody-drug conjugate (ADC) technology platform, has been cleared on its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for its Phase I first-in-human study.
YL201 uses a novel "TMALIN" (Tumor Microenviroment Activable Linker) ADC technology developed at MediLink Therapeutics to resolve potential ADC resistance and stability issues. Preclinical data demonstrated great efficacy of YL201 in various in vivo tumor models, such as non-small cell lung cancer, prostate cancer and esophageal squamous cell carcinoma, and furthermore YL201 shows good tolerability in non-human primates. The clearance of our first IND marks an important milestone for MediLink and brings novel treatment opportunity of this conjugate drug to global cancer patients.
About MediLink Therapeutics
MediLink Therapeutics was established in 2020 by an experienced team with innovative ADC expertise and management skills. The company is committed to developing globally competitive conjugated drugs and building a differentiated proprietary ADC technology platform. MediLink focuses clinical drug development on unmet medical needs, and will continuously expand into new disease areas to serve the global patients.
Contact:
Lei Yang
Email: lei.yang@medilinkthera.com
View original content:https://www.prnewswire.com/news-releases/medilink-therapeutics-receives-fda-clearance-of-ind-application-for-yl201-antibody-drug-conjugate-product-301523508.html
